Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17175021 | 0.77 | TRPV1 (0.37) | TRPV1CHEK1AURKAMAP4K4ABL1 | |
| SCHEMBL23987160 | 0.77 | CHEK1 (0.35) | KDM4ECHEK1AURKAMAP4K4ABL1 | |
| SCHEMBL22571174 | 0.75 | CHEK1 (0.34) | TRPV1LMNAHPGDCHEK1AURKA | |
| SCHEMBL24449967 | 0.75 | CHEK1 (0.34) | CHEK1AURKAMAP4K4ABL1CSF1R | |
| SCHEMBL162683 | 0.74 | — | — | |
| SCHEMBL23986978 | 0.73 | TNKS2 (0.40) | ALDH1A1GLAMAPTKMT2ACHEK1 | |
| SCHEMBL12820646 | 0.73 | — | — | |
| SCHEMBL19364050 | 0.73 | P2RX3 (0.59) | — | |
| SCHEMBL24380201 | 0.72 | TYMS (0.43) | TRPV1HSD17B10KDM4EALDH1A1LMNA | |
| SCHEMBL7513080 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230226186-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-20 | — | — | US | disclosed |
| US-11690915-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20200331957-A1 | CYCLIC DI-NUCLEOTIDES AS STIMULATOR OF INTERFERON GENES MODULATORS | AJ SCIENCES (YIXING) CO., LTD (CN) | 2020-10-22 | — | — | US | disclosed |
| US-20170267681-A1 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | MIDCAP FINANCIAL TRUST, AS AGENT | 2017-09-21 | — | — | US | disclosed |
| US-20170002355-A1 | cGAP-PNA MULTIVALENT PEPTIDE NUCLEIC ACID LIGAND DISPLAY | THE USA, AS REPRESENTED BY THE SECRETARY, DEPART- MENT OF HEALTH AND HUMAN SERVICES (US) | 2017-01-05 | — | — | US | disclosed |
| US-20140148500-A1 | PROGRAMMABLE SELF-ASSEMBLED NANOSTRUCTURES BASED ON SIDECHAIN-MODIFIED PNA FOR THE MULTIVALENT DISPLAY OF LIGANDS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002355-A1 | cGAP-PNA MULTIVALENT PEPTIDE NUCLEIC ACID LIGAND DISPLAY | CGAS, STING1, IAPP | TRPV1 3464/4885HSD17B10 4784/4885KDM4E 4800/4885 |
| US-11690915-B2 | Ras inhibitors | KRAS, NRAS, HRAS | TRPV1 4104/4885HSD17B10 4458/4885KDM4E 3535/4885 |
| US-20140148500-A1 | PROGRAMMABLE SELF-ASSEMBLED NANOSTRUCTURES BASED ON SIDECHAIN-MODIFIED PNA FOR THE MULTIVALENT DISPLAY OF LIGANDS | NCL, PARN, COIL | TRPV1 3717/4885HSD17B10 4527/4885KDM4E 4609/4885 |
| US-20230226186-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | TRPV1 4104/4885HSD17B10 4458/4885KDM4E 3535/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | TRPV1 4755/4885HSD17B10 4436/4885KDM4E 2157/4885 |
| US-20200331957-A1 | CYCLIC DI-NUCLEOTIDES AS STIMULATOR OF INTERFERON GENES MODULATORS | STING1, IRF3, CGAS | TRPV1 1132/4885HSD17B10 3366/4885KDM4E 3160/4885 |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | STING1, IRF3, CGAS | TRPV1 1132/4885HSD17B10 3366/4885KDM4E 3160/4885 |
| US-20230374035-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | TRPV1 4104/4885HSD17B10 4458/4885KDM4E 3535/4885 |
| US-20170267681-A1 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | RNGTT, DUT, RNMT | TRPV1 4408/4885HSD17B10 3419/4885KDM4E 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.